ALLO-647 is an anti-CD52 monoclonal antibody which is designed to be part of the lymphodepletion regimen. ALLO-647 may reduce the likelihood of a patient’s immune system rejecting the engineered allogeneic T cells, and may create a window of persistence during which the engineered allogeneic T cells can actively target and destroy cancer cells.

SparkCures ID 359
Developed By Allogene Therapeutics
Generic Name ALLO-647
Treatment Classifications
Treatment Targets
  • CD52

Clinical Trials


There are no resources, links or videos to display for this treatment.